Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

BACKGROUND: The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed. METHODS: Postmenopausal women with untreated stage I–III HR+/HER2-negative...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamo, Barbara, Bellet, Meritxell, Paré, Laia, Pascual, Tomás, Vidal, Maria, Pérez Fidalgo, José A., Blanch, Salvador, Martinez, Noelia, Murillo, Laura, Gómez-Pardo, Patricia, López-González, Ana, Amillano, Kepa, Canes, Jordi, Galván, Patricia, González-Farré, Blanca, González, Xavier, Villagrasa, Patricia, Ciruelos, Eva, Prat, Aleix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751874/
https://www.ncbi.nlm.nih.gov/pubmed/31533777
http://dx.doi.org/10.1186/s13058-019-1195-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751874/
https://www.ncbi.nlm.nih.gov/pubmed/31533777
http://dx.doi.org/10.1186/s13058-019-1195-z

Ejemplares similares